Waldencast (WALD) to Release Quarterly Earnings on Tuesday

Waldencast (NASDAQ:WALD) will likely be issuing its Q1 2026 results before the market opens on Tuesday, August 4th. Analysts expect Waldencast to post earnings of ($0.17) per share and revenue of $66.1470 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 2:00 AM ET.

Waldencast Trading Up 1.2%

NASDAQ WALD opened at $1.73 on Friday. Waldencast has a 1-year low of $0.72 and a 1-year high of $3.22. The stock has a 50-day moving average of $1.66 and a 200-day moving average of $1.51. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.70 and a quick ratio of 0.97.

Institutional Trading of Waldencast

A number of institutional investors have recently modified their holdings of WALD. JPMorgan Chase & Co. increased its holdings in Waldencast by 12.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 57,702 shares of the company’s stock valued at $114,000 after purchasing an additional 6,516 shares during the period. Barclays PLC raised its position in Waldencast by 11.0% during the 4th quarter. Barclays PLC now owns 66,337 shares of the company’s stock valued at $125,000 after purchasing an additional 6,587 shares during the last quarter. Rhumbline Advisers lifted its holdings in Waldencast by 15.2% in the 1st quarter. Rhumbline Advisers now owns 61,630 shares of the company’s stock worth $185,000 after buying an additional 8,151 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Waldencast by 57.9% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,130 shares of the company’s stock worth $57,000 after buying an additional 8,485 shares during the period. Finally, Invesco Ltd. purchased a new stake in Waldencast in the 2nd quarter worth approximately $26,000. 41.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on WALD. Weiss Ratings cut Waldencast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen raised Waldencast to a “hold” rating in a research note on Saturday, May 30th. Finally, Canaccord Genuity Group raised their target price on shares of Waldencast from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Waldencast presently has an average rating of “Hold” and an average target price of $2.33.

About Waldencast

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.